JP7378401B2 - リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物 - Google Patents

リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物 Download PDF

Info

Publication number
JP7378401B2
JP7378401B2 JP2020536766A JP2020536766A JP7378401B2 JP 7378401 B2 JP7378401 B2 JP 7378401B2 JP 2020536766 A JP2020536766 A JP 2020536766A JP 2020536766 A JP2020536766 A JP 2020536766A JP 7378401 B2 JP7378401 B2 JP 7378401B2
Authority
JP
Japan
Prior art keywords
injectable composition
formula
unilamellar vesicles
pharmaceutically acceptable
iia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020536766A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019135954A5 (https=
JP2021508728A (ja
JP2021508728A5 (https=
Inventor
モッテラム，ラジェシュワ
Original Assignee
サイネクシス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイネクシス，インコーポレーテッド filed Critical サイネクシス，インコーポレーテッド
Publication of JP2021508728A publication Critical patent/JP2021508728A/ja
Publication of JPWO2019135954A5 publication Critical patent/JPWO2019135954A5/ja
Publication of JP2021508728A5 publication Critical patent/JP2021508728A5/ja
Priority to JP2023187032A priority Critical patent/JP2024012452A/ja
Application granted granted Critical
Publication of JP7378401B2 publication Critical patent/JP7378401B2/ja
Priority to JP2025060460A priority patent/JP2025106349A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
JP2020536766A 2018-01-02 2018-12-21 リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物 Active JP7378401B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023187032A JP2024012452A (ja) 2018-01-02 2023-10-31 リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物
JP2025060460A JP2025106349A (ja) 2018-01-02 2025-04-01 リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862612893P 2018-01-02 2018-01-02
US62/612,893 2018-01-02
PCT/US2018/067216 WO2019135954A1 (en) 2018-01-02 2018-12-21 Injectable compositions of triterpenoid antifungals encapsulated in liposomes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023187032A Division JP2024012452A (ja) 2018-01-02 2023-10-31 リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物

Publications (4)

Publication Number Publication Date
JP2021508728A JP2021508728A (ja) 2021-03-11
JPWO2019135954A5 JPWO2019135954A5 (https=) 2022-03-24
JP2021508728A5 JP2021508728A5 (https=) 2022-03-24
JP7378401B2 true JP7378401B2 (ja) 2023-11-13

Family

ID=65024141

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020536766A Active JP7378401B2 (ja) 2018-01-02 2018-12-21 リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物
JP2023187032A Withdrawn JP2024012452A (ja) 2018-01-02 2023-10-31 リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物
JP2025060460A Pending JP2025106349A (ja) 2018-01-02 2025-04-01 リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023187032A Withdrawn JP2024012452A (ja) 2018-01-02 2023-10-31 リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物
JP2025060460A Pending JP2025106349A (ja) 2018-01-02 2025-04-01 リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物

Country Status (27)

Country Link
US (3) US20200338002A1 (https=)
EP (2) EP4137123A1 (https=)
JP (3) JP7378401B2 (https=)
KR (1) KR102694692B1 (https=)
CN (2) CN115998684A (https=)
AU (1) AU2018399599B2 (https=)
CA (1) CA3087176A1 (https=)
DK (1) DK3735226T3 (https=)
EA (1) EA202091626A1 (https=)
ES (1) ES2927051T3 (https=)
HR (1) HRP20221295T1 (https=)
HU (1) HUE060400T2 (https=)
IL (2) IL275758B2 (https=)
LT (1) LT3735226T (https=)
MA (1) MA51514A (https=)
MD (1) MD3735226T2 (https=)
MX (1) MX2020006992A (https=)
PL (1) PL3735226T3 (https=)
PT (1) PT3735226T (https=)
RS (1) RS63687B1 (https=)
SA (1) SA520412362B1 (https=)
SG (1) SG11202006313WA (https=)
SI (1) SI3735226T1 (https=)
SM (1) SMT202200427T1 (https=)
TW (2) TWI857944B (https=)
UA (1) UA126096C2 (https=)
WO (1) WO2019135954A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024012452A (ja) * 2018-01-02 2024-01-30 サイネクシス，インコーポレーテッド リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517909A (ja) 2004-01-14 2007-07-05 ギリアード サイエンシーズ， インコーポレイテッド 薬物送達に有用な脂質ベースの分散物
JP2011530593A (ja) 2008-08-12 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 抗真菌剤
JP2014237729A (ja) 2005-07-19 2014-12-18 インスメッド， インコーポレイテッド 徐放性抗感染剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP5245057B2 (ja) 2006-04-03 2013-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 抗真菌剤
CN101861150B (zh) * 2007-09-28 2014-07-16 默克夏普和道赫莫公司 抗真菌制剂
JP2011518844A (ja) * 2008-04-25 2011-06-30 ナノバイオ コーポレーション 真菌、酵母および糸状菌感染症を治療するためのナノエマルション
AU2009275230A1 (en) * 2008-07-23 2010-01-28 Targeted Delivery Technologies Limited Methods of administering topical antifungal formulations for the treatment of fungal infections
ES2593027T3 (es) * 2009-03-30 2016-12-05 Eisai R&D Management Co., Ltd. Composición liposomal
HRP20220544T1 (hr) * 2015-01-19 2022-08-05 Scynexis, Inc. Nove soli i polimorfi scy-078
CA3087176A1 (en) * 2018-01-02 2019-07-11 Scynexis, Inc. Injectable compositions of triterpenoid antifungals encapsulated in liposomes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517909A (ja) 2004-01-14 2007-07-05 ギリアード サイエンシーズ， インコーポレイテッド 薬物送達に有用な脂質ベースの分散物
JP2014237729A (ja) 2005-07-19 2014-12-18 インスメッド， インコーポレイテッド 徐放性抗感染剤
JP2011530593A (ja) 2008-08-12 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 抗真菌剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024012452A (ja) * 2018-01-02 2024-01-30 サイネクシス，インコーポレーテッド リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物

Also Published As

Publication number Publication date
US20230277455A1 (en) 2023-09-07
LT3735226T (lt) 2022-11-10
EP3735226B1 (en) 2022-08-10
KR20200105875A (ko) 2020-09-09
SMT202200427T1 (it) 2022-11-18
JP2024012452A (ja) 2024-01-30
DK3735226T3 (da) 2022-10-24
JP2025106349A (ja) 2025-07-15
HUE060400T2 (hu) 2023-02-28
SA520412362B1 (ar) 2022-12-15
US20250082574A1 (en) 2025-03-13
CN115998684A (zh) 2023-04-25
HRP20221295T1 (hr) 2022-12-23
SI3735226T1 (sl) 2022-11-30
RS63687B1 (sr) 2022-11-30
BR112020013448A2 (pt) 2020-12-01
EA202091626A1 (ru) 2020-09-22
IL275758B2 (en) 2025-07-01
IL318793A (en) 2025-04-01
WO2019135954A1 (en) 2019-07-11
MD3735226T2 (ro) 2023-03-31
PT3735226T (pt) 2022-09-20
TW201929853A (zh) 2019-08-01
TW202434242A (zh) 2024-09-01
KR102694692B1 (ko) 2024-08-14
EP4137123A1 (en) 2023-02-22
MX2020006992A (es) 2020-09-09
UA126096C2 (uk) 2022-08-10
CA3087176A1 (en) 2019-07-11
NZ765771A (en) 2024-09-27
JP2021508728A (ja) 2021-03-11
MA51514A (fr) 2021-04-07
IL275758A (en) 2020-08-31
IL275758B1 (en) 2025-03-01
AU2018399599A1 (en) 2020-07-16
ES2927051T3 (es) 2022-11-02
TWI857944B (zh) 2024-10-11
SG11202006313WA (en) 2020-07-29
CN111655237B (zh) 2023-02-03
EP3735226A1 (en) 2020-11-11
PL3735226T3 (pl) 2022-12-19
CN111655237A (zh) 2020-09-11
TWI862280B (zh) 2024-11-11
US20200338002A1 (en) 2020-10-29
AU2018399599B2 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
JPH03500650A (ja) ポリエン系マクロライドのプレリポソーム粉末
US20260000656A1 (en) Antifungal agents with enhanced activity in acidic ph
JP2025106349A (ja) リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物
HK40090116A (en) Injectable compositions of triterpenoid antifungals encapsulated in liposomes
HK40040387A (en) Injectable compositions of triterpenoid antifungals encapsulated in liposomes
HK40040387B (en) Injectable compositions of triterpenoid antifungals encapsulated in liposomes
HK40036677B (en) Injectable compositions of triterpenoid antifungals encapsulated in liposomes
HK40036677A (en) Injectable compositions of triterpenoid antifungals encapsulated in liposomes
BR112020013448B1 (pt) Composição injetável, método para preparar uma composição injetável, e, uso da composição injetável
EA045936B1 (ru) Инъецируемые композиции, обладающие противогрибковой активностью, и способы их получения и применения
Grillot et al. Systemic antifungal agents
HK40030410B (en) Antifungal agents with enhanced activity in acidic ph
HK40030410A (en) Antifungal agents with enhanced activity in acidic ph
EA047126B1 (ru) Противогрибковое средство для лечения или профилактики инфекции вульвовагинального кандидоза

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211220

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230728

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231031

R150 Certificate of patent or registration of utility model

Ref document number: 7378401

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150